Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients
about
A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.Dose capping of plerixafor in patients weighing more than 100 kg at one vial led to successful mobilization outcomes and significant cost savings.Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting.Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.
P2860
Q37738995-D62F939D-6E74-4AA5-952E-3C59C2952973Q38771752-59431EB0-2472-4769-A551-85DF6196DF1AQ38880504-730C2959-8972-4C98-B3A6-456B4A4C3A59Q39177577-825578E7-881B-48D3-8770-E33157EF52B5Q40490106-84A9203E-F570-43C7-8AAD-309D6C7170FBQ46654811-370D82F2-6D9F-442E-82DD-BA9418EFD6B9Q48337454-8B2FC0E0-E9AF-4BC7-B523-6888318C65FDQ50092819-F418D2EF-5243-45D0-B03F-A6B4D9D8591CQ53130499-C201A96D-F85C-48E6-B642-95AE3A0B9EC9Q54582789-28995855-F48F-42DC-AF29-C085AB43DA62
P2860
Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Plerixafor is superior to conv ...... in heavily pretreated patients
@ast
Plerixafor is superior to conv ...... in heavily pretreated patients
@en
Plerixafor is superior to conv ...... in heavily pretreated patients
@nl
type
label
Plerixafor is superior to conv ...... in heavily pretreated patients
@ast
Plerixafor is superior to conv ...... in heavily pretreated patients
@en
Plerixafor is superior to conv ...... in heavily pretreated patients
@nl
prefLabel
Plerixafor is superior to conv ...... in heavily pretreated patients
@ast
Plerixafor is superior to conv ...... in heavily pretreated patients
@en
Plerixafor is superior to conv ...... in heavily pretreated patients
@nl
P2093
P2860
P356
P1433
P1476
Plerixafor is superior to conv ...... in heavily pretreated patients
@en
P2093
B Braithwaite
N McGinnity
T Callaghan
U Vithanarachchi
P2860
P2888
P356
10.1038/BCJ.2014.79
P577
2014-10-31T00:00:00Z
P5875
P6179
1042081050